Rheumatoid Arthritis Drugs Market Recorded Hyper Growth in the South Korea Healthcare Industry

 

Rheumatoid arthritis is a disease that causes pain and inflammation in joints. It affects individuals of all ages; however, the geriatric population is highly susceptible to develop this disease. The symptoms of rheumatoid arthritis include pain, stiffness, tender, and swelling of joints. Currently, no cure is available for rheumatoid arthritis. However, certain drugs are used to efficiently control the conditions of rheumatoid arthritis, which include disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and uric acid drugs.

Request For Sample Report@ https://www.alliedmarketresearch.com/request-sample/3753

COVID-19 Impact Analysis:

The World Health Organization (WHO) on January 30, 2020 declared COVID-19 outbreak a public health emergency of international concern. COVID-19 has affected around 210 countries across the globe. According to the Lancet Rheumatology 2020, patients with rheumatoid arthritis who develop COVID-19 infection may be at high risk for developing severe symptoms and additional complications. Some DMARDs commonly used to treat rheumatoid arthritis, such as hydroxychloroquine drug, are being investigated as potential therapy for COVID-19. Moreover, other generally used therapies such as biologics targeting interleukin (IL)-6 (sarilumab, tocilizumab) and IL-1 (anakinra) are being assessed in patients with COVID-19. Thus, COVID-19 infection uplifted growth opportunities for manufacturers of rheumatoid arthritis drugs during the forecast period.

The global rheumatoid arthritis drugs market is segmented into drug class, route of administration, sales channel, and region. Depending on drug class, the market is categorized into disease-modifying anti-rheumatic drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, uric acid drugs, and others. By route of administration, it is segregated into oral and parenteral. On the basis of sales channel, it is fragmented into prescription-based drugs and over-the-counter drugs. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Market Players

• Abbvie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly And Company
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis Ag (Sandoz)
• Pfizer Inc.
• Ucb S.A.

Key Benefits For Stakeholders

• The study provides an in-depth analysis of the rheumatoid arthritis drugs market size along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers rheumatoid arthritis drugs market analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the rheumatoid arthritis drugs market.
• A comprehensive analysis of four regions is provided to determine the prevailing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global rheumatoid arthritis drugs market growth.